Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03893955 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
SponsorAbbVie
Started2019-05-21
View on ClinicalTrials.gov ↗
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

Amendment history 2 changes detected by DataLookout

2026-09-03
Primary completion pushed: 2026-03 → 2027-03
2026-09-03
Completion pushed: 2026-03 → 2027-03
Trial Details
NCT Number NCT03893955
Lead Sponsor AbbVie
Conditions Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors
Enrollment 150 participants
Start Date 2019-05-21
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-02